AVI BioPharma (AVII) Misses Q3 EPS by 1c

November 10, 2008 4:06 PM EST
Get Alerts AVII Hot Sheet
Price: $0.66 --0%

Financial Fact:
General and administrative: 22.18M

Today's EPS Names:
Trade Now! 
Join SI Premium – FREE
AVI BioPharma (Nasdaq: AVII) reports Q3 loss of $0.08, 1 cent worse than the analyst estimate of ($0.07). Revenue for the quarter was $5.2 million, versus the consensus of $5.86 million.

AVI BioPharma, Inc., a biopharmaceutical company, develops therapeutic products based on NeuGene antisense drugs and ESPRIT alternative RNA splicing technology. Its lead product candidate, Resten-NG that completed Phase II clinical trial is targeted at cardiovascular disease.

You May Also Be Interested In

Related Categories